About US
Contact us
-
AstraZeneca's Lynparza scores limited NICE backing for new first-line maintenance useWith competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new2019/7/24
-
Novartis' Entresto flops crucial heart failure trial, imperiling $5B sales goalCardiovascular med Entresto’s blockbuster turn in 2018 was a long time coming for Novartis, which held on toa $5 billion vision for the drug even as its launch lagged. But those dreams took another h2019/7/23
-
Mylan CEO Bresch set to exit after years of controversy—and one last big dealDuring Mylan CEO Heather Bresch's 28-year stint there, the company has utterly transformed into a generics giant—and courted controversy along the way. And now, Bresch says she's stepping aside to cl2019/7/23
-
DOJ indicts 2nd opioid distributor for role in illegally pushing pills despite warning signsWith federal scrutiny mounting on claims it profiteered from the nation’s opioid epidemic, Ohio-based Miami-Luken shuttered its doors for good last year. But if the former company’s leaders thought t2019/7/22
-
AstraZeneca to shell out £12M in severance dispute with workers at former England plantWhen AstraZeneca sold its Avlon, England plant to CDMO Avara in 2016, it was touted as a lifeline for the drugmaker’s 210 on-site employees who faced termination. Three years later, with the plant ba2019/7/22
-
Still on a cash-raising spree, Takeda shops €1.5B European drug sale: reportTakeda’s ax is about to fall again, this time on some over-the-counter and off-patent prescription drugs in Western Europe. The Japanese pharma, still working to pay down debt it incurred for its Shi2019/7/19
-
Novartis, aiming to clean up its rep, sets aside $700M for kickback settlementWith nearly decade-old bribery charges hanging over its head, Novartis has been eager to wriggle out of U.S. prosecutors’ crosshairs. Now, a settlement in the case appears to be in the works—and it c2019/7/19
-
Zolgensma launch 'on track and fully in line' with expectation, says Novartis CEOGene therapy Zolgensma is under the spotlight as Novartis launches what’s known as the world’s most expensive drug. And now, its chief has offered an early glimpse into the rollout. The Zolgensma lau2019/7/18
-
FDA investigators discover key Strides Pharma quality records in shredding roomFDA investigators, particularly in India, have learned it is best to look beyond the production floor, clean rooms and quality control labs when doing inspections. They look around shredders, in tras2019/7/18
-
Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing in breast cancerIn breast cancer, Novartis’ Kisqali is trailing closely behind Eli Lilly’s direct competitor Verzenio. Now it's gained even footing with its rival in England, at least where the country's cost-effect2019/7/17